SCHEMBL5896174

SCHEMBL5896174

O=C(O)/C(=C/c1ccc(-c2cc(Cl)ccc2Cl)o1)NC(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.59
▸ MAPK1 P28482 6/20 0.59
▸ ALDH1A1 P00352 5/20 0.59
▸ HTT P42858 3/20 0.59
▸ MITF O75030 2/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ KDM4E B2RXH2 6/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ SENP1 Q9P0U3 1/20 0.53
▸ LMNA P02545 5/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ GAA P10253 1/20 0.51
▸ MCL1 Q07820 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ HPGD P15428 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896187 1.00 MAPT (0.59) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5896197 1.00 MAPT (0.59) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5896487 0.89 MAPT (0.62) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5896506 0.89 MAPT (0.62) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5896497 0.89 MAPT (0.62) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5897295 0.87 MAPT (0.58) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5897297 0.87 MAPT (0.58) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5897288 0.87 MAPT (0.58) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5895081 0.84 MAPK1 (0.69) MAPTMAPK1ALDH1A1HTTMITF
SCHEMBL5895072 0.84 MAPK1 (0.69) MAPTMAPK1ALDH1A1HTTMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 — — US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 — — US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 — — EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 — — US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 MAPT 3583/4885MAPK1 1713/4885ALDH1A1 832/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPT 3589/4885MAPK1 2559/4885ALDH1A1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback